Sunscreen in Skin Cancer Prevention: The 2025 Review Breakdown
Understanding the clinical evidence behind sun protection is essential for anyone researching skin health and UV defense. In 2025, an extensive paper titled A review of sunscreen in the prevention of skin cancer. appeared in the Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. This single review analyzed published research to assess how consistently sunscreens avert malignancies. Breaking down this review into key numbers, study designs, and outcomes helps clarify what the clinical data actually demonstrates—and where the limits remain.
The 2025 Review: A Single Synthesis of Published Data
The 2025 paper is structured as one narrative review rather than an original clinical trial or laboratory experiment. To gather evidence, the authors performed an extensive search within the PubMed database. Their search strategy focused specifically on existing review articles and clinical literature regarding sunscreen application and oncology outcomes.
The investigators built their literature query around three primary search topics:
- Sunscreen and usage
- Skin cancer
- Sunscreen side effects
Because this work is a literature review, its findings summarize preexisting publications rather than generating fresh experimental datasets. Recognizing this design is critical, as reviews inherently depend on the quality, methodology, and scope of the individual papers they compile.
Three Research Frameworks Analyzed in the Evidence
In evaluating the clinical literature, the review summarized findings drawn across three foundational research formats:
- Observational studies
- Cohort studies
- Randomized controlled trials
Across these varying frameworks, the data underscored that topical sunscreen provides measurable benefits in forestalling skin cancers. Randomized controlled trials offer structured comparative data, while observational and cohort studies track broader population behaviors over time. By examining these three distinct study structures together, the paper assessed real-world usage alongside controlled outcomes.
Evaluating Outcomes Across Three Major Skin Cancers
A core finding of the review is that sunscreen does not demonstrate identical protective effects across every malignancy. The authors evaluated evidence for three distinct forms of skin neoplasia, which are detailed in our guide to different types of skin cancer:
- Melanoma: The review concluded that regular sunscreen use reduces the incidence of melanoma.
- Squamous-Cell Carcinoma: The incidence of squamous-cell carcinoma is also reduced among sunscreen users.
- Basal-Cell Carcinoma: In contrast to melanoma and squamous-cell carcinoma, the documented protective effect of sunscreen on basal-cell carcinoma is relatively less pronounced.
This variance illustrates why sweeping claims about complete sun protection can be misleading. While sunscreen demonstrates clear preventative utility against melanoma and squamous-cell carcinoma, its impact on basal-cell carcinoma appears less pronounced in the clinical literature reviewed.
Two Documented Primary Dermatologic Side Effects
The paper also addressed user safety, examining the adverse events recorded during sunscreen use. According to the data summary, the primary side effects associated with sunscreen application involve localized dermal reactions:
- Dermal irritation
- Skin rash
Beyond these immediate surface reactions, the review noted that there is some indication that UV filter-based sunscreens may harbor carcinogenic properties. Because of these considerations, the authors emphasized that healthcare providers should actively guide individuals regarding product selection rather than assuming all formulations present an identical safety profile.
Two Critical Determinants: Product Type and Adherence
The review emphasizes that achieving preventative benefits is not automatic. The clinical outcome is putatively contingent upon two critical variables highlighted by the study authors:
- Sunscreen Type: Different formulations and UV filters perform differently on the skin. Choosing appropriate formulations, as outlined in our review of sunscreen selection and broad-spectrum protection, plays a direct role in overall defense.
- Adherence to Guidelines: Protection relies heavily on how consistently users follow recommended application guidelines and how frequently they reapply the product.
As the Journal of oncology pharmacy practice review concluded, clinicians must advise patients not only on which specific sunscreen to choose, but also on the necessary frequency of use. Incomplete coverage or irregular application significantly diminishes the protective effects documented in clinical trials.
Study Limitations and Medical Guidance
While the 2025 review provides a helpful synthesis of modern oncology literature, readers should not overstate its conclusions. The paper itself notes that overall protection putatively reflects user habits, frequency of application, and product type. Furthermore, the less pronounced response observed in basal-cell carcinoma underscores that topical products are only one component of comprehensive UV awareness.
For individuals researching tanning methods and skin health, evidence-based habits supervised by a board-certified dermatologist remain the safest path. Unregulated peptides such as melanotan I and melanotan II sold online carry significant health risks, lack regulatory approval, and must never be substituted for medically validated preventative care. Discussing personalized sun safety and routine skin screenings with a licensed doctor ensures your approach is grounded in proven clinical science.
Sources
Published October 28, 2026. Sources are linked in the text. See our Medical Disclaimer.